Pharmaceuticals
YishengBio Announces PIKA recombinant COVID-19 vaccine received Phase I clinical trial IND clearance from New Zealand
BEIJING, Aug. 9, 2021 /PRNewswire/ -- YishengBio Co., Ltd ("YishengBio") today announced that it received IND clearance for PIKA recombinant COVID-19 vaccine (CHO cell, S Protein) to conduct Phase I clinical trial from New Zealand Medicines and Medical Devices Safety Authority ("MEDSAFE"), which ...
2021-08-09 21:00
2907
Life Sciences' Contribution to the US Digital Therapeutics Market to Grow the Fastest amongst all End Users
The US digital therapeutics market is estimated to witness more than three-and-a-half-fold growth reaching$4.54 billion by 2025, at a CAGR of 29.8%, finds Frost & Sullivan SANTA CLARA, Calif., Aug. 9, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis finds that digital therapeutics (DTx) i...
2021-08-09 18:02
2405
Innovent Announces the Establishment of the Scientific Advisory Board
SAN FRANCISCO and SUZHOU, China, Aug. 9, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
2021-08-09 08:04
4653
Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China
HONG KONG, Aug. 5, 2021 /PRNewswire/ -- Akeso, Inc. (9926.HK, the "Company" or "Akeso") announced that the anti PD-1 monoclonal antibody drugPenpulimab monoclonal antibody injection co-developed by the Company with Sino Biopharmaceutical Limited (stock code: 1177.HK), has obtained marketing appr...
2021-08-06 09:39
28390
Brii Biosciences Announces the Completion of Enrollment in the Phase 3 National Institutes of Health (NIH) ACTIV-2 Trial, Evaluating the BRII-196 and BRII-198 Monoclonal Neutralizing Antibody Combination for the Treatment of COVID-19
846 outpatients at high risk of clinical progression have been enrolled in the ACTIV-2 phase 2/3 clinical study, from sites inthe United States, Brazil, South Africa, Mexico and Argentina. The participants are being evaluated for the combined endpoint of hospitalizations and death relative ...
2021-08-05 22:46
4493
ArisGlobal Lauded by Frost & Sullivan for Enabling Life Sciences Companies to Accelerate R&D with Its LifeSphere® Platform
LifeSphere® ably supports clients by expediting decision-making, maintaining compliance, and streamlining collaborations among cross-functional teams SANTA CLARA, Calif., Aug. 5, 2021 /PRNewswire/ -- Based on its recent analysis of the North American clinical development and pharmacovigilance so...
2021-08-05 21:55
2491
China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests and the Company Plans to Apply for NMPA Approval
HAIKOU, China, Aug. 5, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its Candesartan hypertension product passed key bioequivalence tests. The Company plans to use the result...
2021-08-05 21:00
26671
Berry Oncology Completes Series B1 Funding, Attracting Most Venture Capital to Date in Early Cancer Screening Sector
BEIJING, Aug. 5, 2021 /PRNewswire/ -- Berry Oncology Corporation, a member company ofChina's leading early cancer screening firm Berry Genomics, yesterday on its 4th anniversary, announced the completion of a US$99.15 million Series B1 financing round. This brings the total capital raised by the ...
2021-08-05 21:00
2067
Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model
SYDNEY, Aug. 5, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma (CCA) at the Americas Hepato-Pancreato-Biliary Association (AHBP...
2021-08-05 18:00
1295
KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to Manufacture Generic Product for Filing in Japan
TAIPEI, Aug. 5, 2021 /PRNewswire/ -- KYOWA Pharmaceutical Industry Co. Ltd., a premier Japanese pharmaceutical company, has contracted with Bora Pharmaceutical Laboratories Inc. (Zhunan), a division of Bora Pharmaceuticals for the manufacturing of generic product for filing inJapan. KYOWA will be...
2021-08-05 14:50
2106
Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia
SHANGHAI, Aug. 5, 2021 /PRNewswire/ -- Everest Medicines
2021-08-05 13:12
4084
Chinese Multinational Technology Company, HUAWEI, Aligns With Singapore-Based Healthtech Start-up PLANO to Tackle the Global Problem of Myopia
SINGAPORE, Aug. 5, 2021 /PRNewswire/ -- Shenzhen, Guangdong, China, and Singapore – Huawei Technologies Co. Ltd. (hereinafter, Huawei) and Plano Pte. Ltd. (hereinafter, Plano) today announced their partnership to address the global problem of myopia. Through this partnership, Huawei and Plano wil...
2021-08-05 10:00
2172
Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine
GAITHERSBURG, Md., Aug. 4, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has reached an agreement with the European Commission (EC) for the purchase of up to 200 million doses...
2021-08-04 21:10
9113
Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine
HONG KONG, Aug. 4, 2021 /PRNewswire/ -- Insilico Medicine, a global company specializing in the applications of the next-generation machine learning technologies for drug discovery and development, announced today that its AI-powered drug discovery platform had delivered the preclinical candidate...
2021-08-04 18:11
2276
Lumosa Therapeutics Announces Positive Results from LT3001 Phase 2a Clinical Trial in Acute Ischemic Stroke
* LT3001 met primary safety endpoint. No symptomatic intracranial hemorrhage occurred. * LT3001 showed pronounced neurological improvement in the majority of patients with baseline NIHSS≥6 treated with LT3001. * These data suggest that LT3001 has the potential to provide significant clinica...
2021-08-03 22:48
1844
Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®
SEOUL, South Korea, Aug. 3, 2021 /PRNewswire/ -- Yuyu Pharma, a pharmaceutical company based in Korea, and Novartis Korea announced today that the companies have entered into an agreement in which Yuyu will have exclusive distribution rights for the following prescription medicines in Korea: Lami...
2021-08-03 21:00
1893
111, Inc. Enters into Strategic Cooperation Agreement with Zelgen to Develop a New Management Platform for Liver Cancer Patients in China
SHANGHAI, Aug. 3, 2021 /PRNewswire/ – 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced a strategic cooperation agreement with Suzhou Zelgen ...
2021-08-03 20:00
7688
Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans
Yvelise Barrios, MD, PhD, Immunologist and leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behindCoviDTH, joins BioVaxys as scientific adviser VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Aug. 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (C...
2021-08-03 20:00
4917
TCM Lianhua Qingwen shows stable in vitro antiviral effect on the Delta variant: Expert
GUANGZHOU, China, Aug. 3, 2021 /PRNewswire/ -- The latest research findings from the team of Professor Yang Zifeng from the State Key Laboratory of Respiratory Disease inGuangzhou, China, have showed that Chinese medicine Lianhua Qingwen has an effective inhibitory action on the Delta variant of ...
2021-08-03 15:27
2595
Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor
BEIJING, Aug. 3, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) today announced the first patient was dosed in a Phase I/II clinical trial of KRAS G12C inhibitor JAB-21822 inChina. JAB-21822 is Jacobio's innovative in-house small molecule anti-cancer drug, which is designed to target t...
2021-08-03 09:00
3160
Week's Top Stories
Most Reposted
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 296 media titles]
2024-11-28 17:24Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Announcement of "Cyber Sousa Award" Winners of the 16th Xiamen International Animation Festival
[Picked up by 272 media titles]
2024-11-26 16:48
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
12324
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
8375
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
8090
MMA SMARTIES Thailand 2024 - Celebrates Unparalleled Marketing Innovation and Excellence in Thailand
2024-11-23 11:00
7519
WeBank Powers Fusion Bank's Rapid Launch of a Next-Generation Core Banking System
2024-11-22 15:21
5841